| 2.35 0.05 (2.17%) | 09-08 00:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.76 | 1-year : | 3.23 |
| Resists | First : | 2.36 | Second : | 2.76 |
| Pivot price | 2.32 |
|||
| Supports | First : | 1.95 | Second : | 1.7 |
| MAs | MA(5) : | 2.34 | MA(20) : | 2.23 |
| MA(100) : | 2.65  |
MA(250) : | 7.21 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 96.2 | D(3) : | 96.2 |
| RSI | RSI(14): 63.4 | |||
| 52-week | High : | 18.94 | Low : | 0.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BBI ] has closed below upper band by 43.3%. Bollinger Bands are 73.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.37 - 2.38 | 2.38 - 2.39 |
| Low: | 2.18 - 2.2 | 2.2 - 2.21 |
| Close: | 2.33 - 2.35 | 2.35 - 2.37 |
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Thu, 18 Apr 2024
Brickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm Sweating - AOL
Wed, 07 Sep 2022
BBI stock on watch as company changes name to Fresh Tracks Therapeutics (NASDAQ:BBI) - Seeking Alpha
Wed, 07 Sep 2022
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics - GlobeNewswire
Tue, 28 Jun 2022
Brickell Biotech Inc (NASDAQ: BBI) Announces Dosing of First Subject with its BBI-02 - BP Journal
Fri, 26 Nov 2021
Brickell Biotech Inc. (NASDAQ: BBI) Announces Q3 2021 Financial Results and Sofpironium Bromide gel, 15% Study ... - BP Journal
Fri, 05 Nov 2021
The 9 Best Biotech Penny Stocks to Buy For %currentmonth% %currentyear%! - The Stock Dork
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 115 (M) |
| Held by Insiders | 2.48e+006 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 108 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.062e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 486.2 % |
| Return on Equity (ttm) | -85.2 % |
| Qtrly Rev. Growth | 479000 % |
| Gross Profit (p.s.) | 1076.09 |
| Sales Per Share | -430.47 |
| EBITDA (p.s.) | -6.7878e+007 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 4.37 |
| Dividend | 0 |
| Forward Dividend | 181260 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2019-09-02 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|